$SOPH earnings report

SOPHiA GENETICS reported Q3 2026 revenue growth of 25%, improved adjusted EBITDA loss by 31%, and expects full-year revenue at the upper end of its $94 million to $96 million range. AlphAI read SOPHiA GENETICS's Q3 FY2026 filing as solid. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readSOPH · Q3 2026 · ended September 30, 2026

SOPHiA GENETICS reported Q3 2026 revenue growth of 25%, improved adjusted EBITDA loss by 31%, and expects full-year revenue at the upper end of its $94 million to $96 million range.

✓Solid quarter

Revenue grew 25% year-over-year, analysis volume reached a record 118,000, and adjusted EBITDA loss improved to $6.1 million from $8.8 million. Gross margins declined modestly, IFRS net loss increased 1%, and foreign exchange movements could pressure fourth-quarter revenue.

Revenue
$24.3M
25 % y/y
EPS · other
$ (0.24)
Full year 2026 outlook
at the upper end of its previously issued guidance range of $94 million to $96 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3 2026 revenueother$24.27M–25 %
Q3 2026 constant currency revenuenon-GAAP$24.43M–26 %
Q3 2026 cost of revenueother−$8.33M––
Q3 2026 gross profitother$15.93M––
Q3 2026 gross profit marginother65.7 %––
Q3 2026 adjusted gross profitnon-GAAP$17.65M––
Q3 2026 adjusted gross profit marginnon-GAAP72.8 %––
Q3 2026 research and development costsother−$8.29M––
Q3 2026 selling and marketing costsother−$10.58M––
Q3 2026 general and administrative costsother−$14.88M––
Q3 2026 other operating income (expense), netother— (USD thousands)––
Q3 2026 operating lossother−$17.82M––
Q3 2026 interest incomeother$451K––
Q3 2026 interest expenseother−$1.62M––
Q3 2026 fair value adjustments on warrant obligationsother−$1.14M––
Q3 2026 foreign exchange gains (losses), netother$175K––
Q3 2026 loss before income taxesother−$19.96M––
Q3 2026 income tax benefit (expense)other−$314K––
Q3 2026 IFRS loss for the periodother−$20.27M–up 1% year-over-year
Q3 2026 basic and diluted loss per shareother$ (0.24)––
Q3 2026 adjusted EBITDAnon-GAAP−$6.07M–improving 31% year-over-year
Nine months ended September 30, 2026 revenueother$69.27M–25 %
Nine months ended September 30, 2026 constant currency revenuenon-GAAP$67.50M–21 %
Nine months ended September 30, 2026 gross profitother$45.74M––
Nine months ended September 30, 2026 gross profit marginother66.0 %––
Nine months ended September 30, 2026 adjusted gross profitnon-GAAP$50.81M––
Nine months ended September 30, 2026 adjusted gross profit marginnon-GAAP73.3 %––
Nine months ended September 30, 2026 operating lossother−$55.16M––
Nine months ended September 30, 2026 IFRS loss for the periodother−$61.95M––
Nine months ended September 30, 2026 basic and diluted loss per shareother$ (0.81)––
Nine months ended September 30, 2026 adjusted EBITDAnon-GAAP−$24.11M––
Q3 2026 SOPHiA DDM analyses performedother118,000 analyses–19% year-over-year volume growth
Q3 2026 Net Dollar Retentionother118%––
Core genomics customers as of September 30, 2026other551 core genomics customers––
Q3 2026 Liquid Biopsy analysesother4,200 Liquid Biopsy analyses–100%+ year-over-year

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full year 2026 outlook

  • Revenueat the upper end of its previously issued guidance range of $94 million to $96 million
  • NoteAdjusted EBITDA loss between $29 million and $32 million, compared to $41.5 million in FY 2025
  • NotePositive adjusted EBITDA in the second half of 2027

What drove it

  • Record 118,000 analyses performed on SOPHiA DDM™, representing 19% year-over-year volume growth.
  • North America revenue grew 45% year-over-year and APAC revenue grew 33% year-over-year.
  • U.S. revenue grew 41% year-over-year in Q3 2026.
  • The company signed 30 new core genomic customers in Q3 2026, expected to begin generating revenue over the next twelve months.
  • The company closed three material BioPharma deals, including two companion diagnostic programs and a new multimodal AI project.
  • The company signed a notable expansion deal with a leading U.S. military medical center, valued at over $2 million per year.
  • Liquid Biopsy analyses were 4,200 in Q3 2026, up 100%+ year-over-year.

Concerns

  • Reported gross profit margin was 65.7% versus 66.3% in the prior-year period, while adjusted gross profit margin was 72.8% versus 73.1%.
  • IFRS loss for the period was (20,272) (USD thousands), compared with (20,021) (USD thousands) in the prior-year period.
  • The company stated that foreign exchange rate movements at the end of the third quarter, if sustained, would be a headwind to fourth-quarter revenue.
  • The company reported litigation expenses of 931 (USD thousands) in Q3 2026 and stated that expenses related to its defense of lawsuits filed by Guardant Health are expected to continue for the duration of the litigation and may increase in future periods.
  • The company reported restructuring costs of 549 (USD thousands) in Q3 2026.

What to watch

  • Whether foreign exchange rate movements remain a headwind to fourth-quarter revenue.
  • Conversion of the 30 new core genomic customers signed in Q3 2026 into revenue over the next twelve months.
  • Ramp timing for new U.S. accounts, which the company expects to ramp up in 2027.
  • Revenue contribution from the AstraZeneca companion diagnostic programs and the new multimodal AI collaboration.
  • Progress toward the stated objective of positive adjusted EBITDA in the second half of 2027.
  • Sustainability of Net Dollar Retention at 118% and analysis-volume growth.

Balance sheet and cash flow

  • Cash and cash equivalents as of September 30, 2026: $ 93,652 (USD thousands); December 31, 2025: $ 70,289 (USD thousands).
  • Borrowings as of September 30, 2026: 48,147 (USD thousands); December 31, 2025: 47,733 (USD thousands).
  • Nine months ended September 30, 2026 net cash flows used in operating activities: (32,290) (USD thousands); 2025: (27,757) (USD thousands).
  • Nine months ended September 30, 2026 net cash flow used in investing activities: (6,934) (USD thousands); 2025: (5,167) (USD thousands).
  • Nine months ended September 30, 2026 net cash flow provided by/(used in) financing activities: 65,005 (USD thousands); 2025: 30,562 (USD thousands).
  • Nine months ended September 30, 2026 proceeds from sale of common stock in at-the-market offering, net of transaction costs: 15,667 (USD thousands).
  • Nine months ended September 30, 2026 proceeds from sale of common stock in follow-on offering, net of transaction costs: 53,451 (USD thousands).
  • Nine months ended September 30, 2026 capitalized development costs: (7,132) (USD thousands); 2025: (5,697) (USD thousands).

Analysis

SOPHiA GENETICS delivered Q3 2026 revenue of $ 24,267 (USD thousands), up 25 % from $ 19,462 (USD thousands). Constant currency revenue was $ 24,434 (USD thousands), with growth of 26 %. Operating indicators supported the reported growth: SOPHiA DDM analyses reached a record 118,000, Net Dollar Retention rose to 118% from 108%, and core genomics customers increased to 551 from 488. The company also reported 45% year-over-year revenue growth in NORAM, 33% in APAC, and 41% in the U.S.

Gross profit was $ 15,934 (USD thousands), while reported gross profit margin declined to 65.7 % from 66.3 %. Adjusted gross profit was $ 17,646 (USD thousands), and adjusted gross profit margin was 72.8 % versus 73.1 %. The company recorded an operating loss of (17,824) (USD thousands) and an IFRS loss for the period of (20,272) (USD thousands), compared with (20,021) (USD thousands) a year earlier. In contrast, adjusted EBITDA loss improved to $ (6,071) (USD thousands) from $ (8,838) (USD thousands).

Customer and application expansion remained central to the quarter. The company signed 30 new core genomic customers, completed three material BioPharma deals, and signed a multi-year AstraZeneca agreement for two companion diagnostic programs. Liquid Biopsy analyses were 4,200, up 100%+ year-over-year. The company also cited an expansion deal with a leading U.S. military medical center valued at over $2 million per year.

For the first nine months, revenue was $ 69,265 (USD thousands), up 25 %, while IFRS loss for the period was (61,950) (USD thousands) compared with (59,820) (USD thousands). Adjusted EBITDA loss improved to $ (24,108) (USD thousands) from $ (30,338) (USD thousands). Net cash flows used in operating activities were (32,290) (USD thousands), and capitalized development costs were (7,132) (USD thousands). Cash and cash equivalents were $ 93,652 (USD thousands) at September 30, 2026, with borrowings of 48,147 (USD thousands).

Management expects full-year 2026 revenue at the upper end of its $94 million to $96 million range and adjusted EBITDA loss between $29 million and $32 million. The outlook reflects strong business performance but identifies foreign exchange movements at the end of the third quarter as a potential fourth-quarter revenue headwind if sustained. The company reiterated its commitment to crossing over to positive adjusted EBITDA in the second half of 2027.

Management, verbatim

Record analysis volume, strong performance in the U.S. market, and accelerating BioPharma momentum resulted in another excellent quarter as revenue grew 25% year-over-year.

Ross Muken, Chief Executive Officer of SOPHiA GENETICS

We also meaningfully improved adjusted EBITDA by 31%, bringing us closer to profitability and further demonstrating the highly scalable nature of our AI-native platform and business model.

Ross Muken, Chief Executive Officer of SOPHiA GENETICS

Looking ahead, new geographies, exciting new products, and expanded relationships with BioPharma offer meaningful catalysts for future growth.

Ross Muken, Chief Executive Officer of SOPHiA GENETICS

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for financial metrics were not provided.
  • Revenue by reportable operating segment was not provided.
  • Free cash flow was not provided.
  • Share repurchases and dividends were not provided.
  • Forward gross margin, operating expense, and tax-rate guidance were not provided.
  • Nine-month cost of revenue, operating expense line items, interest items, fair value adjustments, foreign exchange gains or losses, and income tax expense are reported in the filing but no corresponding percentage changes were printed for those rows.
  • The previous outlook covered the full year 2026 only, and this quarterly release does not report full-year results, so there is nothing to compare.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Q2 FY2026

AlphAI · Earnings readSOPH · Q2 2026 · ended June 30, 2026

SOPHiA GENETICS Reports Second Quarter 2026 Results

✓Solid quarter

IFRS revenue grew 27% year-over-year, adjusted EBITDA loss improved 27% year-over-year, and full-year revenue guidance was raised. Reported and adjusted gross margins declined year-over-year, while the company remained loss-making and used cash in operating activities.

Revenue
$23.3M
27 % y/y
EPS · other
$ (0.30)
Full year 2026 outlook
$94 million to $96 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenueother$23.31M–27 %
Cost of revenueother−$8.25M––
Gross profitother$15.06M––
Gross profit marginother64.6 %––
Adjusted gross profitnon-GAAP$16.82M––
Adjusted gross profit marginnon-GAAP72.1 %––
Research and development costsother−$8.73M––
Selling and marketing costsother−$11.19M––
General and administrative costsother−$15.20M––
Other operating income, netother$ 5––
Operating lossother−$20.05M––
Interest incomeother$ 231––
Interest expenseother−$1.62M––
Fair value adjustments on warrant obligationsother$ (317)––
Foreign exchange losses, netother$ (519)––
Loss before income taxesother−$22.28M––
Income tax expenseother$ (78)––
Loss for the periodother−$22.36M–flat year-over-year
Basic and diluted loss per shareother$ (0.30)––
Adjusted EBITDAnon-GAAP−$8.83M–improving 27% year-over-year
Constant currency revenuenon-GAAP$22.86M–25 %
Current period constant currency impactnon-GAAP$ (454)––
Six-month revenueother$45.00M–25 %
Six-month gross profitother$29.81M––
Six-month gross profit marginother66.2 %––
Six-month operating lossother−$37.34M––
Six-month loss for the periodother−$41.68M––
Six-month basic and diluted loss per shareother$ (0.58)––
Six-month adjusted EBITDAnon-GAAP−$18.04M––
Six-month net cash flows used in operating activitiesother−$22.81M––
Six-month net cash flow used in investing activitiesother−$5.05M––
Six-month net cash flow provided by financing activitiesother$67.03M––
Cash and cash equivalentsother$107.7M––
Borrowingsother$48.00M––
Total assetsother$198.4M––
Total liabilitiesother$115.2M––
Total equityother$83.12M––

Full year 2026 outlook

  • Revenue$94 million to $96 million
  • NoteAdjusted EBITDA loss between $29 million and $32 million
  • NoteRevenue growth of approximately 22% to 24% year-over-year
  • NoteExpectation of approaching adjusted EBITDA breakeven by the end of 2026
  • NoteExpectation of crossing over to positive adjusted EBITDA in the second half of 2027

What drove it

  • Performed a record 115,000 analyses on SOPHiA DDM™, representing 22% year-over-year volume growth.
  • U.S. revenue grew 64% year-over-year and U.S. volume grew 60% year-over-year in Q2 2026.
  • Liquid Biopsy revenue grew 80% year-over-year in Q2 2026, and Liquid Biopsy volume grew 70%.
  • Net Dollar Retention increased to 117% in Q2 2026 from 107% in Q2 2025.
  • Core genomics customers reached 542 as of June 30, 2026, up from 490 customers a year ago.
  • The company signed 24 new core genomic customers in Q2 2026, expected to begin generating revenue over the next twelve months.
  • Recently signed projects with AstraZeneca, Kartos, and others began to generate revenue.
  • The company signed a multi-year agreement with AstraZeneca to launch two companion diagnostic programs.

Concerns

  • Reported gross profit margin was 64.6 %, compared to 67.0 % in the prior-year period.
  • Adjusted gross profit margin was 72.1 %, compared to 74.4 % in the prior-year period.
  • Operating loss was $ (20,053), compared to $ (18,492) in the prior-year period.
  • Interest expense was $ (1,620), compared to $ (559) in the prior-year period.
  • Net cash flows used in operating activities were $ (22,812) for the six months ended June 30, 2026.
  • The company incurred $ 1,819 of litigation expenses in its six-month adjusted EBITDA reconciliation related to defense of lawsuits filed by Guardant Health.
  • The company incurred $ 1,255 of restructuring costs in Q2 2026.

What to watch

  • Execution against full-year revenue guidance of $94 million to $96 million.
  • Execution against adjusted EBITDA loss guidance of $29 million to $32 million.
  • Conversion of 24 newly signed core genomic customers into revenue over the next twelve months.
  • Implementation progress among the more than half of the 80 customers across 30+ countries signed to adopt the Liquid Biopsy application that had yet to complete implementation.
  • Progress toward approaching adjusted EBITDA breakeven by the end of 2026 and positive adjusted EBITDA in the second half of 2027.
  • Development of the envisioned joint venture with Memorial Sloan Kettering Cancer Center and the two AstraZeneca companion diagnostic programs.

Balance sheet and cash flow

  • Cash and cash equivalents were $ 107,665 as of June 30, 2026, compared to $ 70,289 as of December 31, 2025.
  • Borrowings were $ 47,999 as of June 30, 2026, compared to $ 47,733 as of December 31, 2025.
  • Net cash flows used in operating activities were $ (22,812) for the six months ended June 30, 2026, compared to $ (18,964) in the prior-year period.
  • Net cash flow used in investing activities was $ (5,047) for the six months ended June 30, 2026, compared to $ (2,591) in the prior-year period.
  • Proceeds from sale of common stock in an at-the-market offering, net of transaction costs, were $ 15,667 for the six months ended June 30, 2026.
  • Proceeds from sale of common stock in a follow-on offering, net of transaction costs, were $ 54,048 for the six months ended June 30, 2026.
  • Net cash flow provided by financing activities was $ 67,032 for the six months ended June 30, 2026, compared to $ 32,549 in the prior-year period.

Analysis

SOPHiA GENETICS reported Q2 2026 IFRS revenue of $ 23,310, up 27 % from $ 18,323 in the prior-year period. Constant currency revenue was $ 22,856, up 25 %. Operating activity expanded, with a record 115,000 SOPHiA DDM™ analyses, 22% year-over-year volume growth, Net Dollar Retention of 117%, and 542 core genomics customers as of June 30, 2026. Management identified 64% U.S. revenue growth, 60% U.S. volume growth, 80% Liquid Biopsy revenue growth, and BioPharma project contributions as growth drivers.

Revenue growth did not translate into higher gross margins. IFRS gross profit margin declined to 64.6 % from 67.0 %, while adjusted gross profit margin declined to 72.1 % from 74.4 %. Operating loss widened to $ (20,053) from $ (18,492), as research and development, selling and marketing, and general and administrative costs were each higher than in the prior-year quarter. The net loss was $ (22,356), compared to $ (22,414), while adjusted EBITDA improved to $ (8,834) from $ (12,037).

The company used $ (22,812) of cash in operating activities and $ (5,047) in investing activities during the six months ended June 30, 2026. Financing activities provided $ 67,032, including $ 15,667 from the at-the-market offering and $ 54,048 from the follow-on offering, net of transaction costs. Cash and cash equivalents ended the period at $ 107,665, compared with $ 70,289 at December 31, 2025, while borrowings were $ 47,999. Management stated that an oversubscribed public offering raised approximately $57.5 million in gross proceeds and expects the company has sufficient capital resources to fund its growth objectives.

Management raised full-year 2026 revenue guidance to $94 million to $96 million from the prior range of $92 million to $94 million, and guided to an adjusted EBITDA loss of $29 million to $32 million, compared to $41.5 million in FY 2025. The company also reiterated its expectation of approaching adjusted EBITDA breakeven by the end of 2026 and crossing over to positive adjusted EBITDA in the second half of 2027. Important execution items include revenue conversion from new core genomic customers, further implementation of Liquid Biopsy customers, BioPharma program growth, and progress on the AstraZeneca companion diagnostic programs and the envisioned MSK joint venture.

Management, verbatim

We delivered an outstanding second quarter, growing revenue 27% year-over-year, while also improving adjusted EBITDA loss by 27%.

Ross Muken, Chief Executive Officer of SOPHiA GENETICS

Strong revenue performance was driven by 60% volume growth in the U.S., 70% volume growth in Liquid Biopsy, and accelerating growth in BioPharma.

Ross Muken, Chief Executive Officer of SOPHiA GENETICS

As I step into the role of CEO, my focus will be on converting our world-class AI platform, a hard-won global network, and a decade of scientific credibility into accelerating, profitable growth for years to come.

Ross Muken, Chief Executive Officer of SOPHiA GENETICS

Not in the filing

stated, not guessed
  • Previous-release outlook was not provided, so no actual-versus-prior-guidance comparison is included.
  • Prior-quarter figures and quarter-over-quarter changes for reported metrics were not provided.
  • Reportable segment revenue was not provided.
  • Free cash flow was not reported.
  • Dividends and share repurchases were not reported.
  • Forward gross-margin, operating-expense, and tax-rate guidance was not provided.
  • GAAP measures were not applicable because the company reports its financial statements under IFRS.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about SOPH earnings dates

When is SOPHiA GENETICS's next earnings date?
AlphAI has no date for SOPH yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.